← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
T3d Therapeutics, Inc.
Research Triangle Park, NC
$26,361,868
Total funding
4
Grants
Funding over time
peak $8.1M · FY2015–25$10M$7.5M$5M$2.5M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$26,361,868 · 4
By mechanism
R01$20,365,584 · 1
R44$5,996,284 · 3
Investigators at T3d Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of T3D-959 in Mild to Moderate Alzheimer's Disease Subjects$5,526,539
R01 · FY2021 · AG
Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of T3D-959 in Mild to Moderate Alzheimer's Disease Subjects$5,526,538
R01 · FY2022 · AG
Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of T3D-959 in Mild to Moderate Alzheimer's Disease Subjects$3,102,477
R01 · FY2020 · AG
Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of T3D-959 in Mild to Moderate Alzheimer's Disease Subjects$2,396,962
R01 · FY2020 · AG
Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of T3D-959 in Mild to Moderate Alzheimer's Disease Subjects$2,292,799
R01 · FY2019 · AG
Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of T3D-959 in Mild to Moderate Alzheimer's Disease Subjects$1,520,269
R01 · FY2022 · AG
Clinical Development Enablement â Long Term Rodent Testing of the Carcinogenic Potential of the Alzheimerâs Disease Drug Candidate T3D-959$1,249,334
R44 · FY2023 · AG
Clinical Evaluation of T3D-959 as a Potential Disease Remedial Therapeutic for the Treatment of Alzheimer's Disease$1,127,955
R44 · FY2015 · AG
Phase 2 Enabling Studies of a Candidate Drug Therapy (T3D-959) Regulating Neurometabolism for the Treatment of Huntington's Disease$1,088,768
R44 · FY2022 · NS
Clinical Development Enablement â Long Term Rodent Testing of the Carcinogenic Potential of the Alzheimerâs Disease Drug Candidate T3D-959$1,009,699
R44 · FY2024 · AG
Clinical Evaluation of T3D-959 as a Potential Disease Remedial Therapeutic for the Treatment of Alzheimer's Disease$686,939
R44 · FY2016 · AG
Phase 2 Enabling Studies of a Candidate Drug Therapy (T3D-959) Regulating Neurometabolism for the Treatment of Huntington's Disease$529,782
R44 · FY2023 · NS
Clinical Development Enablement â Long Term Rodent Testing of the Carcinogenic Potential of the Alzheimerâs Disease Drug Candidate T3D-959$203,807
R44 · FY2025 · AG
Clinical Evaluation of T3D-959 as a Potential Disease Remedial Therapeutic for the Treatment of Alzheimer's Disease$100,000
R44 · FY2016 · AG